Abstract: Formulations or products are caused to be active antimicrobials by the addition thereto of at least one effective amount of at least one crystalline mixed metal hydroxide (MMOH) conforming substantially to the formulaLi.sub.m D.sub.d T(OH) (m+2d+3+na) (A.sup.n).sub.a.xH.sub.2 Owhere m is zero to one, D is a divalent metal, d is from zero to 4, T is a trivalent metal, A represents at least one anion or negative-valence radical, (m+2d+3+na) is equal or to greater than 3, (m+d) is greater than zero, and xH.sub.2 O represents excess waters of hydration. The MMOH forms an adduct with, an coats, the microbes, thereby deactivating the microbes.
Type:
Grant
Filed:
September 4, 1990
Date of Patent:
October 13, 1992
Assignee:
The Dow Chemical Company
Inventors:
John L. Burba, III, John L. Alexander, Arthur E. Read, Jr., Wilfred W. Wilson
Abstract: Topical pharmaceutical compositions for the treatment of lesions of the skin or mucous membranes containing a physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the formation of lipoxygenase products, and lysine.
Abstract: Cardioplegia solutions having potassium and chloride ion concentrations selected to give a product approximately equal to the product of the potassium and chloride ion concentrations in blood and blood substitutes have been shown to prevent heart cell swelling during cardioplegia.
Type:
Grant
Filed:
October 17, 1990
Date of Patent:
August 18, 1992
Assignees:
Virginia Commonwealth University, Center for Innovative Technology
Abstract: A method and composition for the preventive and curative treatment of exercise-induced pulmonary hemorrhage in animals. The method comprises administration to the animal of a mixture of urea, alkaline potassium salts and magnesium salts. The composition comprises a mixture of urea, alkaline potassium salts, and magnesium salts, and if required, a pharmaceutically acceptable carrier.
Abstract: A blood substitute suitable for replacing blood in mammalian subjects when performance of surgical procedures at hypothermic temperatures is described. The blood substitute comprises water, electrolytes at physiological concentration, dextran 40 at a concentration sufficient for the blood substitute to achieve a colloidal suspension having a fluid osmotic pressure essentially equivalent to mammalian plasma, HEPES buffer at a physiological pH, dextrose, magnesium ion at a concentration of about 0.01M and potassium ion at a concentration greater than 10 mEq per liter sufficient to prevent or arrest cardiac fibrillation. In one embodiment the blood substitute is a multi-solution system wherein the solutions comprise differing levels of the above-indicated components and are administered sequentially to completely replace a subjects circulating blood.
Type:
Grant
Filed:
May 8, 1990
Date of Patent:
July 14, 1992
Assignee:
Cryomedical Sciences, Inc.
Inventors:
Paul E. Segall, Harold Waitz, Hal Sternberg
Abstract: Processes and compositions are provided for accomplishing fluid therapy using the anions l-lactate, pyruvate, d-betahydroxybutyrate, acetoacetate, or mixtures of such. The racemic d,l-lactate or acetate anion mixtures heretofore used in fluids are now known not to be desirable because they cause adverse and toxic effects when administered to mammals.
Abstract: A method and solution are disclosed for treatment of tissue wounds, particularly ulcerous lesions. The solution comprises a solution of seawater or a sea salt solution to which is added a cholinergic agent to stimulate local vasodilation and neurologic function.
Abstract: The anti-viral effectiveness of conventional anti-viral agents such as acyclovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.
Abstract: A veterinary composition useful for treatment of energy depletion, dehydration and electrolyte imbalance in diarrhoeic neonatal animals consisting essentially of(a) glucose in an amount sufficient to produce a concentration level of from greater than 200 nM to 250 mM when in an aqueous solution,(b) one or more sodium salts in an amount sufficient to produce a sodium ion concentration level of from 60 mM to 120 mM when in an aqueous solution, and(c) one or more chloride salts in an amount sufficient to produce a chloride ion concentration level of 50 mM to 90 mM when in an aqueous solution.
Abstract: Peritoneal dialysis solution with usual electrolyte composition in physiological amounts and with galactose as osmotically active substance in an amount of 1-70 g/l.
Abstract: Nitrogen-free thickeners in aqueous surfactant solutions comprising polyethoxylates of mono- and/or polyunsaturated C.sub.12 -C.sub.22 fatty alcohols having an average degree of ethoxylation of 2 to 5, which also contain 1 to 2 terminal propylene oxide groups attached by condensation instead of the corresponding number of ethylene oxide groups. The products may also be used in admixture with dissolved inorganic electroltye salts and with polyethoxylates of saturated fatty alcohols. These surfactant solutions are useful in the formulation of personal hygiene preparations such as hair shampoos, foam baths, shower baths, handwashing pastes and the like.
Type:
Grant
Filed:
September 9, 1988
Date of Patent:
February 12, 1991
Assignee:
Henkel Kommanditgesellschaft auf Aktien
Inventors:
Holger Tesmann, Hermann Hensen, Wolfgang Hochschon, Uwe Ploog
Abstract: Methods and compositions useful for the treatment and prophylaxis of calcium renal stones in persons with hypocitraturia or undergoing allopurinol therapy are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
Type:
Grant
Filed:
September 27, 1989
Date of Patent:
October 30, 1990
Assignee:
Board of Regents, the University of Texas System
Abstract: According to the invention, a liquid deliquescent composition is substantially uniformly applied to grain, animal feed, animal feed ingredients, hay or poultry litter product, inhibiting moisture migration or translocation in the product and thereby inhibiting the formation of mold-generating accumulations of moisture adjacent the walls of storage containers for grain, animal feed, feed ingredients or hay which are subject to large overnight temperature drops, and similary inhibiting the formation of mold-generating accumulations of moisture adjacent the walls of grain elevators or silos subject to large seasonal temperature drops. Such inhibiting of moisture migration or translocation according to the invention also inhibits the formation of dry zones in grain, animal feed, feed ingredients, hay or poultry litter, thereby inhibiting the generation of dust from such products, including the inhibiting of dust generation during the screw-conveying of grain to storage.
Abstract: This invention relates to compositions comprising electrolytes dissolved in a buffer which is painless when administered by irrigation.This invention also relates to compositions comprising a local anesthetic such as lidocaine, procaine, mepivacaine or marcaine, dissolved in a buffered solution containing salts which do not cause pain when the solutions are administered. The compositions are useful for administration as painless local anesthetics and painless irrigation-anesthetizing solutions for human and animal use. The invention further relates to methods for painless irrigation of wounds and of inducing painless local anesthesia comprising administering an effective amount of the compositions of this invention to an animal.
Abstract: A blood substitute suitable for replacing blood in mammalian subjects when performance of surgical procedures at hypothermic temperatures is described. The blood substitute comprises water, electrolytes at physiological concentration, dextran 40 at a concentration sufficient for the blood substitute to achieve a colloidal suspension having a fluid osmotic pressure essentially equivalent to mammalian plasma, HEPES buffer at a physiological pH, dextrose, magnesium ion at a concentration of about 0.01M and potassium ion at a concentration greater than 10 mEq per liter sufficient to prevent or arrest cardiac fibrillation. In one embodiment the blood substitute is a multi-solution system wherein the solutions comprise differing levels of the above-indicated componants and are administered sequentially to completely replace a subjects circulating blood.
Type:
Grant
Filed:
April 26, 1989
Date of Patent:
May 8, 1990
Assignee:
Cryomedical Sciences Inc.
Inventors:
Paul E. Segall, Harold D. Waitz, Hal Sternberg
Abstract: A pelletized feed supplement is supplied which effectively increases productivity of animals fed high acid producing diets. The pelletized feed supplement can also be used to neutralize stomach acid of humans and to maintain a proper electrolyte balance. A method is taught of producing the pelletized feed supplement which results in a buffering agent which is dissolved gradually, and has a high buffering capacity.
Abstract: Methods and compositions useful for the treatment and prophylaxis of calcium renal stones are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
Type:
Grant
Filed:
February 26, 1987
Date of Patent:
December 19, 1989
Assignee:
Board of Regents of the University of Texas System
Abstract: The anti-viral effectiveness of conventional anti-viral agents such as acylovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.
Abstract: Halophors, e.g., bromophors, comprising a complex of sulfone, e.g., sulfolane, halide ion, e.g., sodium bromide, and halogen, e.g., bromine, are described. Solid, free-flowing halophor compositions of the aforesaid complex and an amorphous siliceous carrier are also described.
Type:
Grant
Filed:
January 16, 1986
Date of Patent:
July 4, 1989
Assignee:
PPG Industries, Inc.
Inventors:
Robert H. Juda, Paritosh M. Chakrabarti, Roger A. Crawford
Abstract: A tissue irrigating solution useful for irrigating animal tissue, such as ocular tissue and neuro tissue, during surgery, contains sodium, potassium, magnesium calcium chloride, and bicarbonate ions as well as dextrose, glutathione, and gamma-amino butyric acid (GABA) or functional analogue(s) of GABA, or a mixture of GABA and such analogue(s) in proportions consistent with the osmotic stability and continued metabolism of the tissue cells. The irrigating solution is prepared by mixing a first basic solution which provides the bicarbonate and a second acidic solution which provides the calcium, magnesium, dextrose and glutathione. The first and second solutions may be stored as stable, sterile solutions for extended periods of time and mixed within 24 hours of use.
Type:
Grant
Filed:
December 31, 1986
Date of Patent:
June 6, 1989
Assignee:
Laboratoires P.O.S.
Inventors:
Guy Andermann, Georges de Burlet, Michel Dietz, Joseph Spittler
Abstract: A blood substitute suitable for replacing blood in mammalian subjects when performance of surgical procedures at hypothermic temperatures is described. The blood substitute comprises water, electrolytes at physiological concentration, dextran 40 at a concentration sufficient for the blood substitute to achieve a colloidal suspension having a fluid osmotic pressure essentially equivalent to mammalian plasma, HEPES buffer at a physiological pH, dextrose, magnesium ion at a concentration of about 0.01M and potassium ion at a concentration greater than 10 mEq per liter sufficient to prevent or arrest cardiac fibrillation. In one embodiment the blood substitute is a multi-solution system wherein the solutions comprise differing levels of the above-indicated componants and are administered sequentially to completely replace a subjects circulating blood.
Type:
Grant
Filed:
October 23, 1990
Date of Patent:
September 22, 1992
Assignee:
Cryomedical Sciences, Inc.
Inventors:
Paul E. Segall, Harold D. Waitz, Hal Sternberg